I am a synthetic chemist and radiochemist who specializes in the discovery and development of targeted imaging agents. I received my PhD degree from the Technical University of Munich, Germany, focusing on the design of peptidomimetics and organometallic molecules.
During a Fellowship at the Center for Systems Biology of Massachusetts General Hospital/Harvard Medical School, I designed small molecule-based PARP1 inhibitors, which were shown to be suitable imaging agents for different forms of cancer in preclinical studies. I also developed GLP1R inhibitors, which were used as intraoperative imaging agents for the visualization of Islets of Langerhans.
At Memorial Sloan Kettering Cancer Center, one of the cornerstones of our research is the design of novel tumor-targeting probes. Our main focus lies in the use of positron emission tomography (PET) technology to generate novel peptidic or peptidomimetic imaging agents, which may be used both for the detection of cancer as well as to monitor chemotherapeutic treatment.
- Clinical Expertise: Radiochemistry
- Languages Spoken: English
- Education: PhD, Technical University of Munich (Germany)
- Fellowships: Massachusetts General Hospital
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more